Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2014

Open Access 01-12-2014 | Research

Antiplasmodial activity of chloroquine analogs against chloroquine-resistant parasites, docking studies and mechanisms of drug action

Authors: Nicolli B de Souza, Arturene ML Carmo, Adilson D da Silva, Tanos CC França, Antoniana U Krettli

Published in: Malaria Journal | Issue 1/2014

Login to get access

Abstract

Background

Given the threat of resistance of human malaria parasites, including to artemisinin derivatives, new agents are needed. Chloroquine (CQ) has been the most widely used anti-malarial, and new analogs (CQAns) presenting alkynes and side chain variations with high antiplasmodial activity were evaluated.

Methods

Six diaminealkyne and diaminedialkyne CQAns were evaluated against CQ-resistant (CQ-R) (W2) and CQ-sensitive (CQ-S) (3D7) Plasmodium falciparum parasites in culture. Drug cytotoxicity to a human hepatoma cell line (HepG2) evaluated, allowed to calculate the drug selectivity index (SI), a ratio of drug toxicity to activity in vitro. The CQAns were re-evaluated against CQ-resistant and -sensitive P. berghei parasites in mice using the suppressive test. Docking studies with the CQAns and the human (Hss LDH) or plasmodial lactate dehydrogenase (Pf LDH) enzymes, and, a β-haematin formation assay were performed using a lipid as a catalyst to promote crystallization in vitro.

Results

All tested CQAns were highly active against CQ-R P. falciparum parasites, exhibiting half-maximal inhibitory concentration (IC50) values below 1 μΜ. CQAn33 and CQAn37 had the highest SIs. Docking studies revealed the best conformation of CQAn33 inside the binding pocket of Pf LDH; specificity between the residues involved in H-bonds of the Pf LDH with CQAn37. CQAn33 and CQAn37 were also shown to be weak inhibitors of Pf LDH. CQAn33 and CQAn37 inhibited β-haematin formation with either a similar or a 2-fold higher IC50 value, respectively, compared with CQ. CQAn37 was active in mice with P. berghei, reducing parasitaemia by 100%. CQAn33, -39 and -45 also inhibited CQ-resistant P. berghei parasites in mice, whereas high doses of CQ were inactive.

Conclusions

The presence of an alkyne group and the size of the side chain affected anti-P. falciparum activity in vitro. Docking studies suggested a mechanism of action other than Pf LDH inhibition. The β-haematin assay suggested the presence of an additional mechanism of action of CQAn33 and CQAn37. Tests with CQAn34, CQAn37, CQAn39 and CQAn45 confirmed previous results against P. berghei malaria in mice, and CQAn33, 39 and 45 were active against CQ-resistant parasites, but CQAn28 and CQAn34 were not. The result likely reflects structure-activity relationships related to the resistant phenotype.
Appendix
Available only for authorised users
Literature
1.
2.
WHO: Guidelines for Treatment of Human Malaria. 2010, Geneva: World Health Organization, 2
3.
WHO: Global Report on Antimalarial Drug Efficacy and Drug Resistance 2000–2010. 2010, Geneva: World Health Organization
4.
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009, 361: 455-457. 10.1056/NEJMoa0808859.PubMedCentralCrossRefPubMed
5.
Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F: Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012, 379: 1960-1966. 10.1016/S0140-6736(12)60484-X.PubMedCentralCrossRefPubMed
6.
Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Duong S, Nguon C, Chuor CM, Saunders D, Se Y, Lon C, Fukuda MM, Amenga-Etego L, Hodgson AV, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su XZ, Ringwald P, Ariey F, Dolecek C, Hien TT, Boni MF: Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet. 2013, 45: 648-655. 10.1038/ng.2624.CrossRefPubMed
7.
Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naudé B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000, 6: 861-871. 10.1016/S1097-2765(05)00077-8.PubMedCentralCrossRefPubMed
8.
9.
Price RN, Douglas NM, Anstey NM: New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009, 22: 430-435. 10.1097/QCO.0b013e32832f14c1.CrossRefPubMed
10.
Graf PC, Durand S, Alvarez Antonio C, Montalvan C, Galves Montoya M, Green MD, Santolalla ML, Salas C, Lucas C, Bacon DJ, Fryauff DJ: Failure of supervised chloroquine and primaquine regimen for the treatment of Plasmodium vivax in the Peruvian Amazon. Malar Res Treat. 2012, 2012: 936067-PubMedCentralPubMed
11.
Gama BE, Lacerda MVG, Daniel-Ribeiro CT, Ferreira-da-Cruz MDF: Chemoresistance of Plasmodium falciparum and Plasmodium vivax parasites in Brazil: consequences on disease morbidity and control. Mem Inst Oswaldo Cruz. 2011, 106: 159-166.CrossRefPubMed
12.
Aguiar AC, Pereira DB, Amaral NS, De Marco L, Krettli AU: Plasmodium vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene characterization in Rondônia, West Amazon, Brazil. Malar J. 2014, 13: 73-10.1186/1475-2875-13-73.PubMedCentralCrossRefPubMed
13.
Hocart SJ, Liu H, Deng H, De D, Krogstad FM: 4-aminoquinolines active against chloroquine-resistant Plasmodium falciparum: basis of antiparasite activity and quantitative structure-activity relationship analyses. Antimicrob Agents Chemother. 2011, 55: 2233-2244. 10.1128/AAC.00675-10.PubMedCentralCrossRefPubMed
14.
Casagrande M, Barteselli A, Basilico N, Parapini S, Taramelli D, Sparatore A: Synthesis and antiplasmodial activity of new heteroaryl derivatives of 7-chloro-4-aminoquinoline. Bioorg Med Chem. 2012, 20: 5965-5979. 10.1016/j.bmc.2012.07.040.CrossRefPubMed
15.
Stocks PA, Raynes KJ, Bray PG, Park BK, O’Neill PM, Ward SA: Novel short chain chloroquine analogues retain activity against chloroquine resistant K1 Plasmodium falciparum. J Med Chem. 2002, 45: 4975-4983. 10.1021/jm0108707.CrossRefPubMed
16.
Solomon VR, Puri SK, Srivastava K, Katti SB: Design and synthesis of new antimalarial agents from 4-aminoquinoline. Bioorg Med Chem. 2005, 33: 2165-
17.
Cunico W, Cechinel CA, Bonacorso HG, Martins MAP, Zanatta N, de Souza MVN, Freitas IO, Soares RPP, Krettli AU: Antimalarial activity of 4-(5-trifluoromethyl-1H-pyrazol-1-yl)-chloroquine analogues. Bioorg Med Chem Lett. 2006, 16: 649-653. 10.1016/j.bmcl.2005.10.033.CrossRefPubMed
18.
Madrid PB, Wilson NT, DeRisi JL, Guy RK: Parallel synthesis and antimalarial screening of a 4-aminoquinoline library. J Comb Chem. 2004, 6: 437-442. 10.1021/cc0340473.PubMedCentralCrossRefPubMed
19.
de Souza NB, Carmo AM, Lagatta DC, Alves MJ, Fontes AP, Coimbra ES, da Silva AD, Abramo C: 4-aminoquinoline analogues and its platinum (II) complexes as antimalarial agents. Biomed Pharmacother. 2011, 65: 313-316. 10.1016/j.biopha.2011.03.003.CrossRefPubMed
20.
Read JA, Wilkinson KW, Tranter R, Sessions RB, Brady RL: Chloroquine binds in the cofactor binding site of Plasmodium falciparum lactate dehydrogenase. J Biol Chem. 1999, 274: 10213-10218. 10.1074/jbc.274.15.10213.CrossRefPubMed
21.
Cortopassi WA, Oliveira AA, Guimarães AP, Rennó MN, Krettli AU, França TC: Docking studies on the binding of quinoline derivatives and hematin to Plasmodium falciparum lactate dehydrogenase. J Biomol Struct Dyn. 2011, 29: 207-218. 10.1080/07391102.2011.10507383.CrossRefPubMed
22.
Carmo AM, Silva FM, Machado PA, Fontes AP, Pavan FR, Leite CQ, Leite SR, Coimbra ES, Da Silva AD: Synthesis of 4-aminoquinoline analogues and their platinum(II) complexes as new antileishmanial and antitubercular agents. Biomed Pharmacother. 2011, 65: 204-209. 10.1016/j.biopha.2011.01.003.CrossRefPubMed
23.
Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986, 89: 271-277. 10.1016/0022-1759(86)90368-6.CrossRefPubMed
24.
do Céu de Madureira M, Paula Martins A, Gomes M, Paiva J, Proença da Cunha A, do Rosário V: Antimalarial activity of medicinal plants used in traditional medicine in S Tomé and Príncipe islands. J Ethnopharmacol. 2002, 81: 23-29. 10.1016/S0378-8741(02)00005-3.CrossRefPubMed
25.
Oduola AM, Milhous WK, Weatherly NF, Bowdre JH, Desjardins RE: Plasmodium falciparum: induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro. Exp Parasitol. 1988, 67: 354-360. 10.1016/0014-4894(88)90082-3.CrossRefPubMed
26.
Trager W, Jensen JB: Human malaria parasites in continuous culture. Science. 1976, 193: 673-675. 10.1126/science.781840.CrossRefPubMed
27.
Lambros C, Vanderberg JP: Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979, 65: 418-420. 10.2307/3280287.CrossRefPubMed
28.
Rieckmann KH, Campbell GH, Sax LJ, Mrema JE: Drug sensitivity of Plasmodium falciparum. An in vitro microtechnique. Lancet. 1978, i: 22-23.CrossRef
29.
Noedl H, Wongsrichanalai C, Miller RS, Myint KS, Looareesuwan S, Sukthana Y, Wongchotigul V, Kollaritsch H, Wiedermann G, Wernsdorfer WH: Plasmodium falciparum: effect of anti-malarial drugs on the production and secretion characteristics of histidine-rich protein II. Exp Parasitol. 2002, 102: 157-163. 10.1016/S0014-4894(03)00051-1.CrossRefPubMed
30.
Peters W, Portus JH, Robinson BL: The four-day suppressive in vivo antimalarial test. Ann Trop Med Parasitol. 1975, 69: 155-171.PubMed
31.
Andrade-Neto VF, Goulart MFO, Silva-Filho JF, Matusalém JS, Pinto MCFR, Pinto AV, Zalis MG, Carvalho LH, Krettli AU: Antimalarial activity of phenazines from lapachol, β-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo. Bioorg Med Chem Lett. 2004, 14: 1145-1149. 10.1016/j.bmcl.2003.12.069.CrossRefPubMed
32.
Krettli AU, Pereira JP, Brener Z: Comparative study of experimental infections in mice inoculated with normal and chloroquine-resistant strains of Plasmodium berghei. Rev Inst Med Trop Sao Paulo. 1969, 11: 94-100.PubMed
33.
Pisciotta JM, Coppens I, Tripathi AK, Scholl PF, Shuman J, Bajad S, Shulaev V, Sullivan DJ: The role of neutral lipid nanospheres in Plasmodium falciparum haem crystallization. Biochem J. 2007, 402: 197-204. 10.1042/BJ20060986.PubMedCentralCrossRefPubMed
34.
Hehre WJ: A Guide to Molecular Mechanics and Quantum Chemical Calculations. 2003, Irvine: Wavefunction, Inc
35.
Halgren TA: Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem. 1996, 17: 490-519. 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P.CrossRef
36.
Rocha GB, Freire RO, Simas AM, Stewart JJ: RM1: a reparameterization of AM1 for H, C, N, O, P, S, F, Cl, Br, and I. J Comput Chem. 2006, 27: 1101-1111. 10.1002/jcc.20425.CrossRefPubMed
37.
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The protein data bank. Nucl Acids Res. 2000, 28: 235-242. 10.1093/nar/28.1.235.PubMedCentralCrossRefPubMed
38.
Thomsen R, Christensen MH: MolDock: a new technique for high-accuracy molecular docking. J Med Chem. 2006, 49: 3315-3321. 10.1021/jm051197e.CrossRefPubMed
39.
Gligorijevic B, Purdy K, Elliott DA, Cooper RA, Roepe PD: Stage independent chloroquine resistance and chloroquine toxicity revealed via spinning disk confocal microscopy. Mol Biochem Parasitol. 2008, 159: 7-23. 10.1016/j.molbiopara.2007.12.014.PubMedCentralCrossRefPubMed
40.
Solomon VR, Haq W, Srivastava K, Puri SK, Katti SB: Synthesis and antimalarial activity of side chain modified 4-aminoquinoline derivatives. J Med Chem. 2007, 50: 394-398. 10.1021/jm061002i.CrossRefPubMed
41.
Solaja BA, Opsenica D, Smith KS, Milhous WK, Terzić N, Opsenica I, Burnett JC, Nuss J, Gussio R, Bavari S: Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A. J Med Chem. 2008, 51: 4388-4391. 10.1021/jm800737y.CrossRefPubMed
42.
Wenzel NI, Chavain N, Wang Y, Friebolin W, Maes L, Pradines B, Lanzer M, Yardley V, Brun R, Herold-Mende C, Biot C, Tóth K, Davioud-Charvet E: Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA. J Med Chem. 2010, 53: 3214-3226. 10.1021/jm9018383.CrossRefPubMed
43.
Iwaniuk DP, Whetmore ED, Rosa N, Ekoue-Kovi K, Alumasa J, de Dios AC, Roepe PD, Wolf C: Synthesis and antimalarial activity of new chloroquine analogues carrying a multifunctional linear side chain. Bioorg Med Chem. 2009, 17: 6560-6566. 10.1016/j.bmc.2009.08.003.PubMedCentralCrossRefPubMed
44.
Egan TJ, Ncokazi KK: Quinoline antimalarials decrease the rate of β-hematin formation. J Inorg Biochem. 2005, 99: 1532-1539. 10.1016/j.jinorgbio.2005.04.013.CrossRefPubMed
45.
Kontoyianni M, McClellan LM, Sokol GS: Evaluation of docking performance: comparative data on docking algorithms. J Med Chem. 2004, 47: 558-565. 10.1021/jm0302997.CrossRefPubMed
46.
Leach AR, Shoichet BK, Peishof CE: Prediction of protein-ligand interactions. Docking and scoring: Successes and gaps. J Med Chem. 2006, 49: 5851-5855. 10.1021/jm060999m.CrossRefPubMed
47.
Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, Lambert MH, Lindvall M, Nevins N, Semus SF, Senger S, Tedesco G, Wall ID, Woolven JM, Peishoff CE, Head MS: A critical assessment of docking programs and scoring functions. J Med Chem. 2006, 49: 5912-5931. 10.1021/jm050362n.CrossRefPubMed
48.
Uren AG, O’Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, Koonin EV, Dixit VM: Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell. 2000, 6: 961-967.PubMed
49.
Meslin B, Barnadas C, Boni V, Latour C, De Monbrison F, Kaiser K, Picot S: Features of apoptosis in Plasmodium falciparum erythrocytic stage through a putative role of PfMCA1 metacaspase-like protein. J Infect Dis. 2007, 195: 1852-1859. 10.1086/518253.CrossRefPubMed
50.
Kitamura K, Kishi-Itakura C, Tsuboi T, Sato S, Kita K, Ohta N, Mizushima N: Autophagy-related Atg8 localizes to the apicoplast of the human malaria parasite Plasmodium falciparum. PLoS One. 2012, 7: e42977-10.1371/journal.pone.0042977.PubMedCentralCrossRefPubMed
51.
Walker DM, Mahfooz N, Kemme KA, Patel VC, Spangler M, Drew ME: Plasmodium falciparum erythrocytic stage parasites require the putative autophagy protein PfAtg7 for normal growth. PLoS One. 2013, 8: e67047-10.1371/journal.pone.0067047.PubMedCentralCrossRefPubMed
52.
Totino PR, Daniel-Ribeiro CT, Corte-Real S, de Fátima F-d-C M: Plasmodium falciparum: erythrocytic stages die by autophagic-like cell death under drug pressure. Exp Parasitol. 2008, 118: 478-486. 10.1016/j.exppara.2007.10.017.CrossRefPubMed
53.
Bursch W: The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ. 2001, 8: 569-581. 10.1038/sj.cdd.4400852.CrossRefPubMed
54.
Rijpma SR, van den Heuvel JJ, van der Velden M, Sauerwein RW, Russel FG, Koenderink JB: Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity. Malar J. 2014, 13: 359-10.1186/1475-2875-13-359.PubMedCentralCrossRefPubMed
55.
Nogueira F, Lopes D, Alves AC, do Rosário VE: Plasmodium falciparum multidrug resistance protein (MRP) gene expression under chloroquine and mefloquine challenge. J Cell An Biol. 2008, 2: 010-020.
56.
Zishiri VK, Joshi MC, Hunter R, Chibale K, Smith PJ, Summers RL, Martin RE, Egan TJ: Quinoline antimalarials containing a dibemethin group are active against chloroquinone-resistant Plasmodium falciparum and inhibit chloroquine transport via the P. falciparum chloroquine-resistance transporter (PfCRT). J Med Chem. 2011, 54: 6956-6968. 10.1021/jm2009698.CrossRefPubMed
57.
Ghobakhloo N, Nateghpour M, Rezaee S, Hajjaran H, Mohebali M, Abedkhojasteh H: Variation of the chloroquine resistance transporter (Crt) gene in chloroquine-resistant and chloroquine-sensitive Plasmodium berghei. Iran J Parasitol. 2008, 3: 39-44.
58.
Frosch AE, Laufer MK, Mathanga DP, Takala-Harrison S, Skarbinski J, Claassen CW, Dzinjalamala FK, Plowe CV: Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. J Infect Dis. 2014, 210: 1110-1114. 10.1093/infdis/jiu216.CrossRefPubMed
59.
Metadata
Title
Antiplasmodial activity of chloroquine analogs against chloroquine-resistant parasites, docking studies and mechanisms of drug action
Authors
Nicolli B de Souza
Arturene ML Carmo
Adilson D da Silva
Tanos CC França
Antoniana U Krettli
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2014
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-13-469

Other articles of this Issue 1/2014

Malaria Journal 1/2014 Go to the issue

Research

In vitro and in vivo combination of cepharanthine with anti-malarial drugs

Research

Factors affecting uptake of optimal doses of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy in six districts of Tanzania

Research

Tumour necrosis factor, interleukin-6 and interleukin-10 are possibly involved in Plasmodium vivax-associated thrombocytopaenia in southern Pakistani population

Research

Analysis of the causes of spawning of large-scale, severe malarial epidemics and their rapid total extinction in western Provence, historically a highly endemic region of France (1745–1850)

Research

Correlation of biomarkers for parasite burden and immune activation with acute kidney injury in severe falciparum malaria

Research

Feasibility of repellent use in a context of increasing outdoor transmission: a qualitative study in rural Tanzania
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits